Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight

<p>After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.</p>